A US-based publicly-listed biotech specialising in immuno-oncology had developed a wide and versatile platform.
The company had advanced its assets into mid-/late-stage development, requiring more capital than it had available.
Having developed the platform, the company had a significant number of development opportunities. However, the company did not have the finance to explore these additional opportunities.
Terminate the phase 3 study leading to a share price increase.
Advance a development partnership with a leading international pharmaceutical player unearthing free drug supply for combination development.
Separate the technology platform from the rest of the company, placing the platform into a separate, privately-held NewCo.
Obtain a sizeable funding commitment from a non-profit organisation focused on oncology.
Having created the private NewCo, Treehill and the company ensured the new platform pursued a range of separate commercial end-markets with NewCo management subsequently building not only a strong pipeline but an investor base as well.
Terminate the phase 3 study leading to a share price increase.
Advance a development partnership with a leading international pharmaceutical player unearthing free drug supply for combination development.
Advance a development partnership with a leading international pharmaceutical player unearthing free drug supply for combination development.
Advance a development partnership with a leading international pharmaceutical player unearthing free drug supply for combination development.
Terminate the phase 3 study leading to a share price increase.
Advance a development partnership with a leading international pharmaceutical player unearthing free drug supply for combination development.
Separate the technology platform from the rest of the company, placing the platform into a separate, privately-held NewCo.
Obtain a sizeable funding commitment from a non-profit organisation focused on oncology.
